Treatment Resistant Depression - Pipeline Review, H1 2015

05:01 EDT 8 Jun 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Treatment Resistant Depression - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-04-28. This 61-page report is available in PDF from $2000.

Treatment Resistant Depression - Pipeline Review, H1 2015


Global Markets Direct’s, ‘Treatment Resistant Depression - Pipeline Review, H1 2015’, provides an overview of the Treatment Resistant Depression’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Treatment Resistant Depression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Treatment Resistant Depression and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides a snapshot of the global therapeutic landscape of Treatment Resistant Depression
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Treatment Resistant Depression and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Treatment Resistant Depression products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Treatment Resistant Depression pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Treatment Resistant Depression Overview 7
Therapeutics Development 8
Pipeline Products for Treatment Resistant Depression - Overview 8
Pipeline Products for Treatment Resistant Depression - Comparative Analysis 9
Treatment Resistant Depression - Therapeutics under Development by Companies 10
Treatment Resistant Depression - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Treatment Resistant Depression - Products under Development by Companies 15
Treatment Resistant Depression - Companies Involved in Therapeutics Development 16
Addex Therapeutics Ltd 16
Amorsa Therapeutics Inc. 17
Edgemont Pharmaceuticals, LLC 18
F. Hoffmann-La Roche Ltd. 19
Johnson & Johnson 20
MarcoPolo Pharmaceuticals SA 21
Otsuka Holdings Co., Ltd. 22
Treatment Resistant Depression - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Combination Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 32
(dextromethorphan hydrobromide + quinidine sulfate) - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
AVP-786 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
basimglurant - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
BC-19 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
EDG-006 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
esketamine hydrochloride - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
EVT-100 Series - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
EVT-103 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
KA-ER12 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
KA-FA - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Small Molecule to Modulate Glutamate Receptor for Anxiety Disorders - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Small Molecules to Inhibit mGluR2 for Central Nervous System Disorders - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Treatment Resistant Depression - Recent Pipeline Updates 50
Treatment Resistant Depression - Dormant Projects 57
Treatment Resistant Depression - Discontinued Products 58
Treatment Resistant Depression - Product Development Milestones 59
Featured News & Press Releases 59
For more information open Treatment Resistant Depression - Pipeline Review, H1 2015.


Original Article: Treatment Resistant Depression - Pipeline Review, H1 2015


More From BioPortfolio on "Treatment Resistant Depression - Pipeline Review, H1 2015"

Quick Search


Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Depression is a serious mental health condition, where sad feelings carry on for weeks or months and interfere with your life. The symptoms include feeling unhappy most of the time (but may feel a little better in the evenings), loosing interest in lif...